Research programme: anti-infectives - Novartis/Merck

Drug Profile

Research programme: anti-infectives - Novartis/Merck

Alternative Names: Anti-infectives research programme - Novartis

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Cubist Pharmaceuticals; Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 23 Feb 2009 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 02 Jul 2002 This programme is still in active development
  • 04 Aug 1999 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top